- Home
- BEAM vs HBI Comparison
BEAM vs HBI Comparison
Compare BEAM & HBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- HBI
- Stock Information
- Founded
- BEAM 2017
- HBI 1901
- Country
- BEAM United States
- HBI United States
- Employees
- BEAM N/A
- HBI N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- HBI Clothing/Shoe/Accessory Stores
- Sector
- BEAM Health Care
- HBI Consumer Discretionary
- Exchange
- BEAM Nasdaq
- HBI Nasdaq
- Market Cap
- BEAM 1.8B
- HBI 1.9B
- IPO Year
- BEAM 2020
- HBI 2006
- Fundamental
- Price
- BEAM $16.19
- HBI $4.82
- Analyst Decision
- BEAM Strong Buy
- HBI Hold
- Analyst Count
- BEAM 11
- HBI 5
- Target Price
- BEAM $48.90
- HBI $5.60
- AVG Volume (30 Days)
- BEAM 1.9M
- HBI 5.9M
- Earning Date
- BEAM 05-06-2025
- HBI 05-08-2025
- Dividend Yield
- BEAM N/A
- HBI N/A
- EPS Growth
- BEAM N/A
- HBI N/A
- EPS
- BEAM N/A
- HBI N/A
- Revenue
- BEAM $63,578,000.00
- HBI $3,522,911,000.00
- Revenue This Year
- BEAM N/A
- HBI $0.59
- Revenue Next Year
- BEAM $10.59
- HBI N/A
- P/E Ratio
- BEAM N/A
- HBI N/A
- Revenue Growth
- BEAM N/A
- HBI 0.65
- 52 Week Low
- BEAM $13.53
- HBI $4.02
- 52 Week High
- BEAM $35.25
- HBI $9.10
- Technical
- Relative Strength Index (RSI)
- BEAM 39.35
- HBI 43.83
- Support Level
- BEAM $15.35
- HBI $4.84
- Resistance Level
- BEAM $17.47
- HBI $5.16
- Average True Range (ATR)
- BEAM 0.90
- HBI 0.14
- MACD
- BEAM -0.07
- HBI -0.03
- Stochastic Oscillator
- BEAM 24.71
- HBI 5.83
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About HBI Hanesbrands Inc.
Hanesbrands manufactures basic and athletic apparel under brands including Hanes, Playtex, Maidenform, Bali, Berlei, and Bonds. The company sells wholesale to discount, midmarket, and department store retailers as well as direct to consumers through stores and e-commerce. Hanesbrands is vertically integrated as it produces nearly 75% of its products in company-controlled factories in more than three dozen nations. Hanesbrands distributes products in the Americas and Asia-Pacific. The company was founded in 1901 and is based in Winston-Salem, North Carolina.